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1. Introduction 
According to WHO, in 2010, there were 8.8 million (range, 8.5-9.2 million) incident cases of 
TB and 1.1 million (range, 8.5-9.2 million) deaths from TB among HIV-negative cases and an 
additional 0.35 million (range, 0.32-0.39) deaths from HIV-associated TB (WHO 2011). An 
examination of the map of estimated incidence rates by country and the breakdown of 
national figures in social strata rapidly reveals that global statistics conceal profound 
inequalities in the present intra- and inter-country distribution of the disease. Ninety-five 
percent of the global TB disease and TB death burden is found in poor countries. In highly 
industrialized countries, TB is currently limited to socially marginalized and other poor 
high-risk groups such as IV drug users, migrants from developing countries, and, over the 
past 30 years, HIV-infected persons. 
Prison inmates1 constitute a high risk-group for tuberculosis (TB) in both developing and 
the industrialized countries. Infection and disease rates remain much higher – from 5 up to 
more than 80 times – compared to national averages (Conninx R et al. 1995; Aerts et al. 2006; 
Dara et al. 2009). In their majority, inmates originate from marginalized populations 
characterized by poor socio-economic living conditions and associated poor life-styles, the 
over-representation per se of multiple high-risk groups already being a significant factor in 
explaining the markedly higher TB incidence and prevalence in prison populations. Greater 
population susceptibility include risk factors as urban dwelling, crowding, poor housing 
with lack of ventilation, limited access to health services and, at individual level, smoking 
and alcohol use, HIV-infection, exposure to indoor air pollution, diabetes mellitus, and 
under-nutrition (Rieder 1999; Lönnroth et al. 2009, 2010; Murray et al. 2011). Imprisonment 
conditions, globally worsening along a downward gradient of per capita gross domestic 
product, amplify those risk factors. Prisons tend to be overcrowded with poorly ventilated 
cells. The proximity of large numbers of individuals for an extended time in such conditions 
facilitates TB transmission. Moreover, prison populations often suffer from mal-nutrition or 
under-nutrition, in particular in low- and low-middle income countries. Also, the latter 
sometimes bear the burden of high or intermediate TB endemicity and generalized HIV-
endemics with penitentiary health services being inexistent, sub-standard or difficult to 
access. Prisons thus constitute an ideal environment for TB transmission. 
                                                 
1 The term « prison » refers in this text to all places of detention, jails (pre-trial detention) as well as 
prisons (detention of sentenced prisoners). The terms “inmates” or “prisoners” are used alternatively, 
referring to all categories of prisoners, sentenced prisoners, remand prisoners, female, male and juvenile 
prisoners.  
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TB in prisons does not only affect prisoners (but also prison guards or visitors). An 
habitually important yearly turn-over of prison populations make prisons a reservoir for TB 
transmission to the community at large. TB is spread by released prisoners who had been 
infected by TB in prison and are at risk of progression from latent TB infection (LTBI) to TB 
disease, prisoners with TB disease not diagnosed in prison, those under treatment but still 
not cured, and prisoners with sub-standard treatment. The way TB in prison influences TB 
and TB control in general populations has been explored by recent research. Stuckler et al. 
(2008) established a clear relationship between rises in incarceration rates and increased TB 
incidence and multi-drug resistant TB prevalence rates in Eastern European and Central 
Asian countries. Increases in the size of prison populations accounted for a 20.5% increase in 
TB incidence in the countries studied from 1991 to 2002. Based on these observations and on 
the fact that patterns of communicable diseases are thought to be influenced by the existence 
of pockets of high transmission, Basu et al. (2011) modeled the role of what they referred to 
as “institutional amplifiers” in the dynamics and control of tuberculosis epidemics. Prisons 
play the role of an “institutional amplifier” of TB with, similarly like, mines and communal 
hospital wards among others. Using this model, they demonstrated that even a substantial 
increase in case detection and treatment success rates, the traditional control measures, has 
little effect on the overall population incidence as long as hubs of transmission continue to 
exist. According to these authors, a key intervention to reduce TB incidence, prevalence and 
mortality in a community would consist in limiting the number of persons entering 
institutional amplifiers.  
This preliminary remark shows that neglecting TB prevention and control in prison settings 
could have serious health consequences for both prisoners and the civilian population, in 
particular in those in middle-low and low income countries where incarceration rates are 
high, where TB control is poor, and where HIV infection rates are high. 
2. The burden of TB in prisons 
Many observational studies in the USA and Eastern Europe have reported the burden of TB 
in prisons, although they are largely heterogeneous due to differences in study design, 
study populations, sampling methods, and the quality of their methodology. Retrospective 
and/or point prevalence studies prevail. They document prevalence of TB infection and 
disease in new prison entrants, exposure to and transmission of TB infection and 
progression to TB disease within prison populations including prison guards, as well as 
transmission of TB from within prisons to extramural civilian populations. In the late 1970s, 
the discovery of two cases of infectious TB in a State prison in Arkansas in the US prompted 
a careful study evidencing rapid intramural spread of the infection, higher morbidity due to 
TB in prisons in compared to the general population and the transmission of the disease 
from a former inmate to individuals outside the prison (Stead 1978). With the transient 
rising incidence of TB in the late 1980s in the US, caused by prematurely dismantled TB 
services and fuelled, in parallel, by the emerging HIV epidemic, TB among prison 
populations received increased attention by researchers. The yearly number of published 
studies concerning TB in prisons as reported by MedLine and other databases started 
increasing. In 1989, a dramatic increase in the incidence of TB in prisons in New York State 
was reported with over half of the prisoners with the disease also having AIDS or infected 
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with HIV. (Braun et al. 1989; Darbyshire 1989) Outbreaks of multi-drug-resistant TB in New 
York State prisons in 1990/91 alerted US public health authorities and the international 
community (Valway et al. 1993, 1994; Drobniewski 1995). Nosocomial (MDR-)TB 
transmission from inmates to prison staff was reported from a California prison by CDC in 
1993 (CDC 1993). An initial survey of TB incidence in a large number of States in nursing 
homes and correctional facilities in the US showed the aggregate TB incidence rate for 
inmates in correctional facilities to be 3.9 (95%CI: 3.35-4.49) times higher than the rate for 
persons of a similar age not incarcerated, thus more systematically confirming former 
observational evidence from individual prisons. (Hutton 1993) Other reports from the US 
which followed confirmed these findings. Increased public funding for TB control efforts 
and the consequent implementation of direct observed therapy (DOT) in high incidence 
areas and populations reversed TB incidence rates from 1993 onwards. In jails and prisons, 
however, better controlled TB also remained a major public health concern (Kendig 1998; 
MacNeil et al. 2005). Subsequent studies concentrated on specific determinants and risk 
factors such as increasing TB infection rates associated with increased time spent in the jail 
system (Bellin et al. 1993), HIV-infection and TB among risk groups such as intravenous 
drug users (IDU) (Pelletier et al. 1993), molecular demonstration on intramural transmission 
(Valway 1991; Ijaz et al. 2004), or the evaluation of control measures (Curtis et al. 1994; 
MacIntyre et al. 1997; Klopf 1998; CDC 2006). Reports on TB in prisons of Western European 
countries experiencing an evolution similar to that of the US soon confirmed the US 
findings. Studies conducted in Spanish prisons reported high prevalence of TB infection and 
illness upon admission in jail, described risk factors as HIV-infection, IDU status, 
malnutrition, or immigrant status. TB transmission in prisons, first described by 
conventional epidemiological methods, was underpinned by molecular techniques from of 
the 1990s. March et al. (2000) described 14 unsuspected active chains of TB transmission 
involving 65 patients in Barcelona prisons system combining conventional epidemiological 
techniques with DNA fingerprinting of M. tuberculosis. Recent transmission accounted for 
almost half of the incident cases, confirming observations made in Madrid prison 
population during the same period (Martin et al. 1994; Chaves F et al. 1997; Fernandez-
Martin et al. 2000). In 2000, a study evaluated high TB incidence rates using molecular 
techniques in French prisons (Hanau-Berçot et al. 2000). In 2002, a systematic data collection 
by questionnaire in 52 European countries with 22 countries responding revealed a median 
TB notification rate of 232 per 100 000 inmates (0-17 808), highlighting the vulnerability of 
prisoners to TB, with the prison populations of Eastern European countries being the most 
affected (Aerts et al. 2006). 
After the disintegration of the former USSR with subsequent economic liberalization the 
downward trends in notification of tuberculosis observed from the 1950s to the 1990s 
reversed throughout all former Soviet Union States. At the same time, the average age of TB 
patients declined, reflecting high levels of recent transmission. From the 1990s onward, a 
growing number of studies reported the high burdens of TB, in particular MDR-TB, in 
prisoners in the former USSR Republics (Drobniewski 1995 ; Drobniewski et al. 1996; 
Conninx et al. 1998; Kimerling et al. 1999; Aerts et al. 2000). Although there is in recent year 
a tendency towards a reduction in TB incidence among prison inmates, a higher proportion 
of TB patients among prisoners have MDR strains than in patients outside prison. A 
challenge is, too, the rising number of people infected with HIV.  
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TB is a major public health problem in Africa which also has a high prevalence of HIV 
infection. Active case finding surveys from Ivory Coast and Malawi reported, for the first 
time, high prevalence and incidence rates of pulmonary TB in an African prison in the 
1990s (Nyangulu et al. 1997; Koffi et al. 1997). Cross-sectional studies from Tanzania 
(Rutta et al. 2001), Botswana (CDC Report 2003), Cameroun (Noeske et al. 2006) and 
others followed, all confirming high TB prevalence rates among inmates and suggesting 
TB prevalence being several fold higher in prison than among the civilian population. A 
review of all relevant English publications on TB in prisons in Sub-Saharan Africa (SSA) 
performed by O’Grady et al. (2011) concluded that there is evidence of an increasing 
prevalence of active TB in prisons in SSA with drug resistant TB increasingly being 
detected. In terms of the driving factors, the study identified HIV, living conditions, 
including overcrowding and poorly ventilated cells, as well as malnutrition associated 
with low immunity. Concerning the root causes of this situation, the authors identified 
lack of public funding and mismanagement of meager resources. In addition, prison 
health services were found to be insufficient.  
Reports and studies from other continents confirmed the overall trend. Ferreira et al. 
reported high incidence rates of TB among incarcerated female prisoners, HIV-infection 
being a major risk factor in a Brazilian prison (1998). The observations were confirmed for 
other prison populations by study results from a Rio de Janeiro prison (Sanchez et al. 2005). 
A TB survey in Taiwan during 1998/99 based on mass radiographic screening showed high 
TB prevalence in all 29 jails and prisons studied (Chiang et al. 2002). TB prevalence and 
incidence among Thai prison inmates were shown to exceed by large those in the 
comparable civilian population (Sretrirutchai et al. 2002; Jittimanee et al. 2007). In the 
Karachi central prison, TB appeared to be 3.75 times higher than in the general population of 
the town (Rao 2004). A TB surveillance study in correctional institutions in Hong Kong over 
the period 1999-2005 found very high TB prevalence among prisoners before and within the 
first months of incarceration (Wong et al. 2008). 
In spite the overwhelming published evidence of TB in prisons as a permanent and, 
perhaps, even a growing problem, some significant gaps persist on our understanding of TB 
in prisons as highlighted in the editorial of a recently published systematic review on 
studies evaluating the incidence of latent tuberculosis infection and TB in prisons 
worldwide and among the general population attributable to the risk of prison-to-
community TB propagation (Baussano et al. 2010). It is still unclear how much TB there is in 
prisons, and it is not possible to give accurate estimates of the increased incidence of TB over 
community rates; the impact of specific prison conditions on TB transmission is yet to be 
evaluated; as is the fraction of TB among the general population due to disease among 
incarcerated groups. 
3. Epidemiology of TB in prisons 
Following the tuberculosis classification of the American Thoracic Society and the United 
States Centre for Disease Control (CDC, now Centre for Disease Control and Prevention), 
Rieder (1999) proposed a model allowing the distinction of four major stages for 
comprehending the dynamics of TB.  
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Fig. 1. A simplified model for tuberculosis epidemiology.  
Figure adapted from Rieder (1999), p9. 
Adapting this model to the conceptualization of the epidemiological framework for 
understanding the dynamics of tuberculosis in prisons, we will briefly discuss exposure to 
TB, infection with TB, and TB disease in prison before discussing TB control policies and 
strategies.   
3.1 Exposure to tubercle bacilli in prison 
The main factors determining the risks of exposure to tubercle bacilli are”… the number of 
incident infectious cases, the duration of their infectiousness and the number and nature of 
interactions between a case and a susceptible contact per unit of time of infectiousness” 
(Rieder (1999), p11). Concerning exposure to tubercle bacilli in prisons, the following 
practical observations could be made: (1) Empirically, a significant number of infectious 
cases is generally present in prison settings; (2) such cases tend to be infectious for a 
prolonged duration, either because they are not diagnosed (at entrance, during stay) or they 
are diagnosed late or are not treated at all treated or are poorly-treated; (3) infectious cases 
are in close and prolonged human contact in overcrowded and poorly ventilated cells.  
3.2 Infection with tubercle bacilli in prison 
The infectious bacterial disease is caused by M. tuberculosis. Humans are the principal 
reservoir for the M. tuberculosis complex with the pathogenic species M.tuberculosis, M. bovis, 
and M. africanum, the first being the most frequent cause of TB disease.  Most commonly, TB 
affects the lungs. TB is an almost exclusively airborne infection caused by tubercle bacilli 
which spreads as infectious droplet nuclei. The link between the transmission of TB 
infection and overcrowding is a well-known phenomenon since the exploration of 
aerobiology in the 1950s and 1960s by Wells, Riley and their co-workers. Beggs et al. (2003) 
reviewed alternative epidemiological models representing the transmission of tuberculosis 
in confined spaces. The authors identified the following factors as crucial for effective TB 
transmission in confined spaces: long exposure periods, sufficient number of infectious 
droplet, small room volume, high occupancy density, low ventilation rate, proximity to the 
infector, and the infectiousness of the incident case. However, the number of infectious 
nuclei required to infect humans with any airborne infection is unknown. Regarding the 
infection of humans to become infected, it is difficult to measures factors like the virulence 
of the TB strain and the resistance of infected individual comes into play, as well as factors 
involved in the dynamics of the infection. 
Exposure TB infection
Infectious 
tuberculosis 
Non-infectious 
tuberculosis 
Risk 
factors 
Risk 
factors 
Risk 
factors 
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There are currently two main tools available for determining infection with MTB, namely: 
the tuberculin skin test (TST) and interferon-gamma release assays (IGRAs). Tuberculin, a 
concoction of antigens produced from killed tubercle bacilli, was first introduced by Koch. 
Subsequently, to increase the specificity of the tuberculin test was purificated, and the dose 
and administration technique standardized. Depending on the epidemiological situation (TB 
prevalence, presence of atypical mycobacteria, presence of HIV infection or other immune-
compromising factors), the diameter of TST induration can indicate the probability of TB 
infection. Over the past decade two commercial have been developed and FDA-approved. 
IGRAs have become widely endorsed in high-income countries for diagnosis of latent TB 
infection (LTBI) and several guidelines on their use have been issued (Masurek et al. 2010). 
However, following a very recent Policy Statement, WHO concludes that there is 
insufficient data and low quality evidence on the performance of IGRAs in low- and middle-
low income countries, typically those with a high TB and/or HIV burden, that IGRAs are 
more costly and technically complex to conduct than the TST and, as such, replacing TST by 
IGRAs as a public health intervention in resource-constrained settings is not recommended 
(WHO 2011). An overall conclusion can be that neither IGRAs nor TST can accurately 
predict the risk of infected individuals developing active TB disease nor that they can be 
used for the diagnosis of active TB; that in prison settings in high-income countries, IGRAs 
can play a key role in the diagnosis of latent TB infection; that TST in prisons in low and 
middle-low income countries is of limited value given the overall TB infection rate of the 
population and the HIV infection burden. Studies suggest that HIV-infected individuals are 
more likely to be infected after exposure to MTB (Daley et al. 1992). 
In their systematic review of available published evidence on incident latent tuberculosis 
infection (LTBI) Baussano et al. (2010) identified six studies, 5 from the US and one from 
Brazil, all dating more than ten years. The median estimated annual incidence rate ratio 
(IRR) for LTBI was 26.4 (interquartile range: 13.0-61.8). The authors also estimated the 
fraction of LTBI in the general population attributable (PAF) to within-prison exposure to 
MTB for each study. The median estimated PAF for LTBI was 13.1% (8.1%-30.0%) for high-
income countries and 6.3% (2.7%-17.2%) for studies from middle-low-income countries. 
These findings suggest that the within-prison spread of LTBI is likely to substantially affect 
the incidence of LTBI and TB in the general population.   
3.3 Progression to tuberculosis disease in prisons 
An estimated one-third of the human population is infected with MTB. Most of it does not 
develop TB disease. Why a particular person does or does not develop TB disease after 
having been infected by the tubercle bacilli is difficult to determine. On the other hand, a 
series of factors have been identified as being are more or less strongly associated with 
progression to TB disease once infected with MTB. Rieder (1999, p64) summarizes a 
selection of these risk factors together with their strength of association with the disease. 
Prison inmates are in particular concerned by the following among those factors (according 
to the strength of association): HIV infection, TB infection acquired less than one year ago, 
underweight and the quantity of the infecting dose. The first two factors have been 
identified in population based studies and the other two observed in numerous case-control 
studies. The strongest risk factor for developing TB is infection with HIV. The risk of disease 
after infection is 10 percent per year among people living with HIV without ART, compared 
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to 10 percent per lifetime among those who are negative. There is evidence that TB infection 
among HIV-infected patients progresses to TB more rapidly than among those without HIV 
infection. Habitually, inmates are characterized not only by one, but several factors at a 
time.  
How can the magnitude of the TB problem in prison populations be quantified? Rieder et al. 
(2011) discuss in a recent paper the critically different calculations for epidemiological 
indicators of the TB burden in prisons. Case definition, depending on screening criteria and 
length of stay in prison, are as critical as the use of appropriate numerator and denominator 
data. For measuring TB prevalence the authors propose medical screening including TB 
screening at entry with clear case definition and appropriate bacteriological examinations, 
discarding cases diagnosed in the first 3 months of stay as cases prevalent at entry. Using a 
simple fictitious data set, the authors show the limitation of cross-sectional prevalence 
surveys as an instrument for assessing time trends in prevalence. For measuring TB 
incidence rate (person-time of observation at risk of developing the disease), the most 
appropriate measure for estimating the magnitude of the TB problem in a prison setting, the 
authors propose as denominator the exact date of entry, excluding the first 3 months, and 
the exact date of exit (occurrence of TB, release, end of the observation period).  
Baussano et al. in their above-cited study identified only nineteen available published 
studies answering the criteria for assessing the risk of incident TB disease within prisons. 
They calculated the estimated median annual IRR for TB which was 23.0 (11.7-36.1). 
However, all but three of the studies retained for the review were dated from during the last 
century and only two had been carried out in low(-middle) income countries (Ivory Coast, 
Brazil), confirming the need to sustain research efforts in view of further up-to-date and 
accurate estimates on the increased incidence of TB in prisons. 
4. TB control in prisons
2
 
The control of TB in prisons and other congregate settings has to take in account the 
entrance point prevalence of infection among institutional residents (and staff), the potential 
for reactivation, the role of transmission within the institution, the potential for detection of 
infection and disease, the potential for prevention and treatment of disease, and the 
potential of the building environment to favor transmission (Nardell 1989). Effective 
chemotherapy is the single most important factor in reducing infectiousness in any situation 
and at any stage of the disease. This requires an effective TB control program with early case 
finding and subsequent successful treatment. Since the early 1990s, the principles of 
prevention, diagnosis, treatment, and care of TB have been codified by WHO in the so-
called DOTS strategy (DOTS=directly observed treatment, short course). Key elements are 
political commitment with increased und sustained financing; case-detection through 
quality assured bacteriology; standardized treatment with supervision and patient support; 
an effective pharmaceutical supply and management system; and a monitoring and 
evaluation system and impact measurement. The DOTS strategy was expanded in 2006 to 
The Stop TB Strategy (WHO 2010a) and launched by the Stop Tuberculosis Partnership in a 
Global Plan to Stop TB in 2010 (WHO 2010b). Its objectives and components apply, in 
                                                 
2 Cf. for the following: WHO 2007a 
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general, to TB control in prisons as well. And corresponding comprehensive guidelines on 
how to control and prevent TB in prisons are available since 1998 (Maher et al. 1998; Bone et 
al. 2000; Bock 2000; WHO 2007a; Dara et al. 2009). These guidelines, however, are seldom 
implemented in developing countries. And even in developed countries the strict and 
competent application of this recommendation is still hampered. Sosa et al. (2006) reported a 
tuberculosis outbreak in a correctional facility after two recently discharged inmates were 
diagnosed with TB. Despite prolonged symptoms and abnormal chest radiographs, the 
index case was not diagnosed while incarcerated and fifty three presumably exposed 
inmates and ten of 485 correctional staff had a conversion of their TST. – Taking as guiding 
principles the elements of the DOTS strategy and taking in account the six components of 
The Stop TB Strategy the following text will resume essentials of TB control strategies in 
prisons. The above cited guidelines provide the necessary additional technical details. 
4.1 Political commitment with increased and sustained financing 
Health care services and national TB services commonly are under the responsibility of a 
ministry of (public) health. Prison health care mostly is under a different ministry (Justice, 
Internal Affairs or other).  For these latter ministries in charge, in particular in low- and 
middle-income countries, prison health stands seldom on a priority list. Consequently, 
prison health services are as a rule grossly underfunded. This underfunding influences 
negatively all components of the prison health system, the service delivery, the health 
workforce, infrastructures and medical products and technologies, the information system, 
financing of the users, the technical leadership and the overall governance. TB control 
cannot act as the main leverage for changing fundamentally this situation. National TB 
programmes (NTP), however, are generally well-structured and dispose of detailed 
technical guidelines. Preventive, diagnostic and treatment procedures and means, supply of 
drugs and laboratory consumables, recording and reporting tools, indicators for monitoring 
and evaluation are well defined. In addition, the principle of equivalence requires that 
prisoners have access to the standards of health care as the general population. Moreover, 
most PNTs in high-burden countries benefit today from external funding. Experience has 
clearly shown that prison TB programmes should be coordinated with and integrated in 
civil-sector TB programmes. Improved collaboration or integration contributes to 
strengthening the overall health system and make benefit a habitually weak prison health 
system. Linkage to the civilian sector has the additional advantage of facilitating treatment 
follow-up of release prisoners. 
4.2 Case detection, including control of MDR and HIV 
The DOTS strategy traditionally relies on passive case finding, meaning that TB cases are 
waited for presenting themselves spontaneously to health services in order to get diagnosed 
and treated. International guidelines (WHO 2007b) recommend on entry into prison a 
medical examination that should include TB screening. We saw that prison inmates belong 
rather to minorities or migrant groups or other segments of the population in which TB 
occurs with a higher incidence. The implementation of active case finding strategies should 
be standard. - One is the screening of new prison entries for active TB disease; this 
recommendation is valid or all type of prisons. Various screening tools have been proposed 
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and assessed, varying from symptom based (clinical) screening including anamnesis with 
regard to past or present TB treatment, over chest radiography, TST or IGRA, or a 
combination of this methods. What screening tools are used has to depend on NTP 
guidelines, local feasibility, and available means. Results of clinical scores may depend on 
the setting were they are applied and should be tested and adapted. The diagnosis of 
pulmonary TB (PTB) cannot be based neither on the result of chest radiography nor of TST 
or IGRA. According to WHO recommendations, all PTB B suspects should undergo 
appropriate bacteriological sputum examination. Sputum negative PTB suspects should be 
diagnosed according to the national NTP guidelines. An incomplete network of smear 
microscopy sites inside the prison system can be completed by collaboration with the civil-
sector TB microscopy network. - The usefulness of periodic screening during the stay in 
prison is much debated, but its implementation seems unavoidable in high TB incidence 
prisons or compartments of prisons. Mathematical modeling of the TB epidemiological 
dynamic according to control strategy shows that also passive TB detection may remain a 
priority in TB control in general populations, it appears insufficient in highly TB-endemic 
prisons to produce a rapid decline in TB incidence (Legrand et al. 2008). Likewise, Uys et al. 
(2011) calculated TB transmission possibilities in low and high prevalence areas and settings 
and came to the conclusion that in high prevalence settings transmission is relatively 
unresponsive to changes in the number of infectious people. He coins the term of 
“transmission elasticity” to describe this phenomenon and he warns against excessively 
optimistic projections regarding the effectiveness of ‘habitual’ control strategies. For TB 
control in prison settings he strongly recommends two measures: ventilation and 
consequent contact tracing. – Finally, contact investigation around a newly detected case 
within the prison has been recommended. The mathematical modeling is confirmed by an 
observation published by Noeske et al. (2011) according to which consequent TB screening 
at entrance and active contact tracing are not able to keep up with TB transmission 
dynamics in largely overcrowded and non-ventilated cell blocks.  
In high-income low-incidence settings like in the US, TST or IGRA for documenting TB 
infection in inmates at entrance or during prison stay as well as in prison staff is recommended. 
In low-income high-burden settings, this testing for LTBI is of limited value as a majority of 
young individuals are TB-infected and/or have received BCG vaccination which makes 
difficult the interpretation of the test. However, where a national policy for TB prevention in 
HIV infected individuals exists, the test might have a place in a range of instruments applied for 
excluding active TB and deciding for isoniazid (INH) or similar TB prophylaxis.  
Ideally, all TB suspects should in addition to sputum smear microscopy undergo drug 
susceptibility testing (DST). Again, implementation of this policy depends on the local 
feasibility and the available means. In any case, prison inmates have to have access to the 
same facilities as the general population. 
Seen the close association between HIV and TB, provider initiated voluntary counselling 
and HIV testing should be an integral part of the prison’s TB control programme. Ideally, to 
all prisoners who are screened for TB a voluntary HIV test should be proposed. For 
prisoners tested positive, the whole range of further diagnostic exploration and prophylactic 
and definite treatment (ART) should be made available and accessible. 
www.intechopen.com
 Public Health – Social and Behavioral Health 
 
442 
4.3 Treatment with supervision and patient support 
Treatment and management of TB obey the same principles in prison as in the civil sector. 
At first glance, directly observed treatment seems easily to maintain as prisoners are in one 
place and always present. However, when prison health personnel are lacking or not 
motivated, observation of adherence to treatment is difficult. Charging prisoners with 
dispensing TB drugs leaves the correct administration of medications to the alea of multiple 
informal hierarchies and power structures. Ensuring that every dose of drugs is taken 
directly observed remains a challenge. 
Another challenge are prisoners released while still on treatment. Formal referral with forms 
is basic, but not sufficient. Good experiences have been made by combining sensitization of 
the patient for the necessity to complete treatment, an agreement together with the patient 
on where and how to complete treatment, and social workers – or NGO members – 
constituting a kind of mediator between patients, the prison health service and the civil TB 
dispensary network susceptible to receive the once released prisoner. This needs mostly 
external funding as do incentive packages which are used in some settings to motivate 
patients.        
4.4 Information, education and communication (IEC) for prisoners and prison staff 
The evidence base for information, education and communication (IEC) for prisoners and 
prison staff is relatively weak compared with that for the other elements of the DOTS 
strategy. Most studies conclude that the effectiveness of current educational efforts in 
influencing prisoners‘ behavior remains largely unknown. In particular, studies have 
pointed out that education and counseling are not of much use to prisoners if they do not 
have the means to act on the information provided while they are in prison. Recognizing 
that prisons and other closed settings are important settings for IEC programs for both 
prisoners and staff about HIV and other infectious diseases, well-designed programs should 
be implemented in all prisons and other closed settings. Written materials should be 
appropriate for the educational level in the population in prisons. Furthermore, prisoners 
and staff should participate in the development of educational materials. Where possible, 
education delivered for prisoners by the prison system should be supplemented by peer 
education programs. In particular, prisoners must be provided with the prevention 
measures. 
4.5 Drug supply and management system 
The NTP must be made entirely responsible and capable of providing sufficient and 
adequate drugs and other consumables to cover the need of all patients in the civil sector as 
well as in prisons. 
4.6 Monitoring, evaluation and impact measurement 
The recording and reporting system in many low(-middle) income and high TB burden 
countries is weak. The causes for lack of motivation for prison health staff to report correctly 
are multiple: Lack of time because of personnel shortage, of essentials like registers, 
treatment cards, even stationary, together with poor training and supervision, and little use 
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of data for analysis. Regularly, too, prison administration intervenes in the technical 
reporting process for political reasons (too many deaths shed a bad light on the 
administration). Where there TB registers, treatment cards and report instructions they 
might differ from those of the TB program. For epidemiological purposes and better follow-
up of patients the recording and reporting system for TB in prison should be identical with 
that of the civil sector. When a prison is collaborating closely with a civil sector diagnostic 
and/or treatment center without self having his status, patient management tools should be 
doubled in order to allow the prison health staff to follow-up the prison’s TB patients 
according to the national guidelines. Reporting should be done to the civil-sector TB-
program and, if needed on the basis of a written agreement, supervision and evaluation 
should be done together with or in close coordination with the NTP.   
4.7 Infection control 
To reduce the risk of TB transmission by infectious patients to susceptible individuals (other 
prisoners, staff, and visitors), early diagnosis and prompt treatment, but also the separation 
of patients during the period of infectiousness is recommended. The consultation room 
should be well ventilated as should the wards reserved for infectious TB patients. Patients 
should be educated with regard to cough hygiene. Whether personal protection (respirators 
for staff, disposable masks for patients, staff, and visitors) and engineering measures 
(negative ventilation for example) can be used will depend on available financial means.  
5. Conclusion 
At present, about 10 million people are incarcerated world-wide. The majority among them 
is at increased risk for TB which is largely a curable disease. TB prison control guidelines 
recommend technical solutions mainly formulated in operational public health terms. 
However, even most comprehensive TB control programs  cannot succeed unless there is a 
fundamental change in confinement conditions like overcrowding, poor ventilation, under-
nutrition, but also informal hierarchies, corruption and violence with consequences for 
access to health services contribute decisively to maintain the vigorous and vicious circle of 
TB transmission in prisons. Until then, inmates are doubly punished, incarcerated and 
incessantly exposed to TB, their situation remaining a shame to public health and to human 
rights.  
6. Annex 
TB control programmes in prisons: What would be a minimum standard? 
The ideal TB control programme in a prison would include the following: 
• government structures supporting TB programmes in both the civil-sector and 
penitentiary systems; 
• written agreement on collaboration and coordination between prison and civil-sector 
TB programmes; 
• prevention through the early detection of infectious cases; avoidance of overcrowding; 
good nutrition, ventilation and light; clear definition of infectious zones with clear policies 
on how to reduce transmission; and the use of masks and/or personal respirators; 
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• complete access to TB diagnosis and treatment for all prisoners entering the prison 
system; 
• adequate treatment in line with national TB programme guidelines, including those for 
prisoners with MDR-TB and TB-HIV coinfection, using DOTS and an uninterrupted 
supply of drugs of guaranteed quality; and 
• a guarantee by prison and civil medical personnel of continued treatment for infected 
individuals following their release from prison. 
The penitentiary system must have: 
• continuing human resource development that ensures an adequate number of staff with 
satisfactory background education and continuous training; 
• a mechanism in place for timely investigation of TB suspects and early detection of 
individuals with active TB and their treatment; 
• a network of laboratories carrying our quality-assured smear microscopy; 
• drug susceptibility testing in a centralized laboratory of ensured quality, either in the 
civil sector or in the prison; 
• a supply of quality second-line drugs for prisoners suffering from MDR-TB once the 
capacity to test prisoners for drug resistance is in place; and 
• recording and reporting in close coordination with the civil sector. 
Source:  
World Health Organization. Regional Office for Europe. Status Paper on Prisons and 
Tuberculosis. Copenhagen 2007 (p23). 
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